Dr Lal PathLabs, which entered capital market during December 2015, has posted strong performance during the first quarter ended June 2016 and its net profit improved by 29.5 per cent to Rs.39.82 crore from Rs.30.74 crore in the similar period of last year. After the public issue, its equity capital increased to Rs.82.74 crore from Rs.55 crore and EPS for the quartet ended June 2016 worked out to Rs.4.81 as against Rs.5.61 in the last period. Its EBDITA improved by 24.5 per cent to Rs.66.41 crore from Rs.53.32 crore. The company's sales improved by 17.7 per cent to Rs.222.83 crore from Rs.189.29 crore
With better financial performance, the company's scrip moved by Rs.11.15 in the afternoon session on BSE to Rs.972.60. The scrip touched to highest level at Rs.1,045.75 on April, 11 2016.
Dr Arvind Lal, chairman and managing director, said, I am delighted to share the Q1 2016 financial and operating results of the company which have shown a healthy growth of nearly 18%. I am pleased to inform that our persistent pursuit and efforts to grow our brand and provide better diagnostic services to a nation where there is an immense and urgent need for quality healthcare, has translated in us not only fulfilling our passion but has also generated positive results. Our continuous initiatives to innovate and expand have enabled us stay ahead on our growth curve, in a sector which we believe is highly dynamic and competitive.”
He added, “We are confident that with the support and commitment of our teams we will continue to deliver high quality services to our patients and drive growth and create significant value for all our stakeholders.”